3 Clinical implications of the differential antibody response in mild-moderate SARS-CoV-2: a prospective multi-centre cross-sectional study

IntroductionSerological testing can augment delayed case identification programmes for Severe Acute Respiratory Syndrome coronoravirus-2 (SARS-CoV-2) Immunoassays employ anti-nucleocapsid (anti-NP;the majority) or potentially neutralising anti-spike (including anti-receptor binding domain;anti-RBD) antibody targets, yet correlation between assays and variability arising from disease symptomatology remains unclear We explore these possibly differential immune responses across the disease spectrum MethodsA multicentre prospective study was undertaken via a SARS-CoV-2 delayed case identification programme (08 May-11 July 2020) Matched samples were tested for anti-NP and anti-RBD (utilising an ‘inhouse’ double-antigen bridged assay), reactivity expressed as test/cut-off binding ratios (BR) and results compared A multivariate linear regression model analysed age, sex, symptomatology, PCR positivity, anti-NP, and anti-RBD BRs Participants were followed up for possible reinfection Results902 individuals underwent matched testing;109 were SARS-CoV-2 PCR swab positive Anti-NP, anti-RBD immunoassay agreement was 87 5% (95% CI 85 3–89 6), with BRs strongly correlated (R=0 75) PCR confirmed cases were more frequently identified by anti-RBD (sensitivity 108/109, 99 1%, 95% CI 95 0–100 0) than anti-NP (102/109, 93 6%, 95% CI 87 2–97 4) Anti-RBD identified an additional 83/325 (25 5%) cases in those seronegative for anti-NP Presence of anti-NP (p<0 0001), fever (p=0 005), or anosmia (p=0 002) were all significantly associated with an increased anti-RBD BR Age was associated with reduced anti-RBD BR (p=0 052) Three cases with evidence of seroconversion (anti-RBD seropositive) presented with subsequent reactive PCR results, two of which coincided with first time onset of Public Heath England SARS-CoV-2 symptoms ConclusionsSARS-CoV-2 anti-RBD shows significant correlation with anti-NP for absolute seroconversion, and BRs Higher BRs are seen in symptomatic individuals with significantly higher levels seen in those with fever and anosmia The degree of discordant results (12 5%) limits the use of anti-NP as a stand-alone for delayed case finding programmes Similarly, this discordance limits the utility of non-neutralising anti-NP assays in place of potentially neutralising anti-RBD to infer possible immunity ** this abstract presentation was awarded an Honourable Mention